<DOC>
	<DOCNO>NCT00723606</DOCNO>
	<brief_summary>This local registration study confirm hypothesis efficacy , tolerability safety ziprasidone IM ( intramuscular ) Chinese population agitation schizophrenia</brief_summary>
	<brief_title>A Randomized , Open-Label , Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<criteria>Male female Chinese subject age 1865 year ( include 65 ) screening . Subjects meet ICD10 ( Classification Mental Behavioral Disorders ) criterion schizophrenia ( F20.X ) . Subjects acute phase schizophrenia appropriate receive intramuscular medication least 3 day History clinically significant physical illness especially myocardial infarction , non compensatory heart failure etc . Subjects receive investigational agent previous 3 month prior screen . Use antipsychotic agent within 12 hour parenteral benzodiazepine within 4 hour prior randomization study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Intramuscular ziprasidone , agitation , efficacy safety</keyword>
</DOC>